Syncromune™
Agustin Gago has an extensive work experience in the biopharmaceutical and medical device industry. Agustin currently serves as the Chief Business Officer at syncromune, a clinical stage biopharmaceutical company specializing in intratumoral immunotherapy for metastatic cancers. Prior to that, they worked as the General Manager Global Consulting at DASH INTERNATIONAL. Agustin also held the position of Executive Vice President Chief Business Officer at ImmunSYS Inc. where they played a key role in business development. Agustin Gago served as the Executive Vice President and Chief Commercial Officer at InspireMD, where they led the company's efforts in manufacturing and commercializing embolic protection systems. Agustin also worked as the Executive VP, Global Marketing & Sales at DELCATH SYSTEMS, INC. and as the VP International Oncology Surgery Sales at ANGIODYNAMICS, INC. Earlier in their career, they held various roles at E-Z-EM Inc, including VP Global GI Business Unit and VP INTERNATIONAL OPERATIONS. Agustin has a strong background in international sales and has successfully managed business operations in Europe, Japan, the Pacific Rim, Latin America, and the Middle East.
Agustin Gago holds a Bachelor of Science degree in Business Management from Hofstra University.
This person is not in any teams
This person is not in any offices
Syncromune™
1 followers
Syncromune™ is a privately held, clinical stage biopharmaceutical company dedicated to the development of better immunotherapies for metastatic solid tumor cancers. We are at the forefront of developing combination immunotherapies, which several thought leaders consider to be the future of cancer therapy. We are committed to bringinglife-changing treatments to patients with unmet medical needs by fighting cancer in a new way. The company is currently developing Syncrovax™, a proprietary platform technology that uses a combination approach to synchronize the timing and location of tumor antigen release with the functional activation and education of immune cells. An in situ vaccine is created from the patient’s own tumor antigens, making it a personalized treatment for each patient. The platform is designed to optimize T cells and the immune system to treat metastatic solid tumors where other therapies have failed.